NYSE:PVCT
Provectus Pharmaceuticals, Inc Stock News
$0.183
-0.0172 (-8.58%)
At Close: Mar 28, 2024
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
08:00am, Thursday, 15'th Feb 2024
KNOXVILLE, TN, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for Oral Presentation at 2022 International Society of Ocular Oncology (ISOO) Congress
02:00pm, Wednesday, 16'th Feb 2022 GlobeNewswire
KNOXVILLE, TN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of uveal melanoma metastatic to the liver (mUM) ( NCT00986661 ) will be presented at the 20 th Congress of the International Society of Ocular Oncology (ISOO), to be held June 17-21, 2022 in Leiden, The Netherlands.
KNOXVILLE, TN, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from historical clinical trials and expanded access studies of investigational cancer immunotherapy
KNOXVILLE, TN, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium)
KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium) f
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines tested
KNOXVILLE, TN, May 25, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the State of Tennessee, as part of its fiscal year 2021-2022 budget, has directed funding in the amount of
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693 0 67)
KNOXVILLE, TN, March 31, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-tr
KNOXVILLE, TN, March 30, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/678,133,
KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872, which